Table II.
Sampling of therapeutic compounds in development towards a range of diseases of the inner ear, including disease target, state of development, and current status.
| Company | Therapeutic | Developed for | Category | Description | Status |
|---|---|---|---|---|---|
| Quark Pharmaceuticals | AHLi | Acute Hearing Loss-Apoptosis Prevention | siRNA | Temporarily inhibits expression of p53 tumor repressor gene | Pre-clinical, IND Submission 2009 |
| Sound Pharmaceuticals | SPL-128 | Regeneration | siRNA | Temporarily inhibits expression of cyclin- dependent kinase inhibitor IB | Pre-clinical |
| Merck & Co. | - | Apoptosis Prevention | siRNA | Temporarily inhibits expression of Rb 1 | Pre-clinical |
| Kinex Pharmaceuticals | KX1-004 | MHL, Cisplatin Ototoxicity | Small Molecule | Src inhibitor | Pre-clinical |
| Adherex | STS | Cisplatin Ototoxicity | Antioxidant | Sodium Thiosulfate | Orphan |
| GenVec | TherAtoh | Regeneration | Gene | Human atonal gene Hath1 vector | Pre-clinical |
| Auris Medical | AM-111 | MHL, Aminoglycoside Ototoxicity | Small Molecule | Block JNK MAPK mediated apoptosis from stress injury | Orphan, Phase IIb |
| Living Cell Technologies | NeurotrophinCell | Degeneration Prevention | Cell | Pig cells encapsulated in alginate beads (500 microns) | Pre-clinical |
| Otonomy | OTO-104 | Meniere’s Disease | Steroid | intratympanic Injection | Phase 1b clinical trial |
| Neurosystec | NST-001 | Tinnitus | NMDA antagonist | Osmotic pump | Phase 1b clinical trial |